@article{10.11648/j.cnn.20200401.12,
  author = {Matthew Koch and Mehr Nasir-Moin and Scott Raymond and Christopher Stapleton and Thabele Leslie-Mazwi and James Rabinov and Aman Patel},
  title = {LVIS Blue as a Stand-alone “Flow Diverter”},
  journal = {Clinical Neurology and Neuroscience},
  volume = {4},
  number = {1},
  pages = {5-10},
  doi = {10.11648/j.cnn.20200401.12},
  url = {https://doi.org/10.11648/j.cnn.20200401.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cnn.20200401.12},
  abstract = {Flow diversion fundamentally changes the treatment approach towards intracranial aneurysms. Most currently available devices established efficacy and safety data in the proximal anterior circulation; the distal and posterior circulations remain areas of active research. LVIS Blue is a stent with 28% metal coverage approved for use as a coil adjuvant. Some studies indicate potential “flow diverter” properties. We sought to evaluate the LVIS Blue as a stand-alone “flow diverter” for the treatment of intracranial aneurysms. We performed an observational single-center study to evaluate initial occlusion and occlusion at six months follow-up for patients with distal or posterior circulation aneurysms treated with the LVIS Blue as a “flow diverter” at our institution. Ten aneurysms were treated over the course of two years with six-month angiographic follow-up. Seven lesions were in the distal anterior circulation and were unruptured (five anterior communicating artery, one M2 middle cerebral artery, one pericallosal). Three were posterior circulation (two basilar tip aneurysms, one P2 posterior cerebral artery aneurysm). Follow up demonstrated treatment effect in nine of ten aneurysms (four complete aneurysm occlusions, five lesions with decreased size and flow). One lesion showed no treatment response. No ischemic or hemorrhagic complications were noted during placement or clinical follow-up. LVIS Blue can function safely as a “flow diverter” in the distal and posterior circulations. Further data regarding long-term efficacy is needed.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - LVIS Blue as a Stand-alone “Flow Diverter”
AU  - Matthew Koch
AU  - Mehr Nasir-Moin
AU  - Scott Raymond
AU  - Christopher Stapleton
AU  - Thabele Leslie-Mazwi
AU  - James Rabinov
AU  - Aman Patel
Y1  - 2020/02/04
PY  - 2020
N1  - https://doi.org/10.11648/j.cnn.20200401.12
DO  - 10.11648/j.cnn.20200401.12
T2  - Clinical Neurology and Neuroscience
JF  - Clinical Neurology and Neuroscience
JO  - Clinical Neurology and Neuroscience
SP  - 5
EP  - 10
PB  - Science Publishing Group
SN  - 2578-8930
UR  - https://doi.org/10.11648/j.cnn.20200401.12
AB  - Flow diversion fundamentally changes the treatment approach towards intracranial aneurysms. Most currently available devices established efficacy and safety data in the proximal anterior circulation; the distal and posterior circulations remain areas of active research. LVIS Blue is a stent with 28% metal coverage approved for use as a coil adjuvant. Some studies indicate potential “flow diverter” properties. We sought to evaluate the LVIS Blue as a stand-alone “flow diverter” for the treatment of intracranial aneurysms. We performed an observational single-center study to evaluate initial occlusion and occlusion at six months follow-up for patients with distal or posterior circulation aneurysms treated with the LVIS Blue as a “flow diverter” at our institution. Ten aneurysms were treated over the course of two years with six-month angiographic follow-up. Seven lesions were in the distal anterior circulation and were unruptured (five anterior communicating artery, one M2 middle cerebral artery, one pericallosal). Three were posterior circulation (two basilar tip aneurysms, one P2 posterior cerebral artery aneurysm). Follow up demonstrated treatment effect in nine of ten aneurysms (four complete aneurysm occlusions, five lesions with decreased size and flow). One lesion showed no treatment response. No ischemic or hemorrhagic complications were noted during placement or clinical follow-up. LVIS Blue can function safely as a “flow diverter” in the distal and posterior circulations. Further data regarding long-term efficacy is needed.
VL  - 4
IS  - 1
ER  - 

Copy | Download